Osimertinib in Pulmonary Manifestations: Two Case Reports and Review of the Literature.
Osimertinib
disease response
ground-glass opacities
pneumonitis
rechallenge
review
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
23
10
2019
revised:
04
11
2019
accepted:
06
11
2019
entrez:
29
12
2019
pubmed:
29
12
2019
medline:
10
6
2020
Statut:
ppublish
Résumé
Osimertinib is an oral, irreversible epidermal growth factor receptor inhibitor that is associated with various pulmonary manifestations including transient asymptomatic pulmonary opacities (TAPOs) and pneumonitis. We present a case of a 61-year-old female with Stage IV lung adenocarcinoma, who developed bilateral ground glass opacities on her chest-computed tomography (CT) three months after initiating osimertinib. Her imaging findings were thought to represent lymphangitic carcinomatosis responding to chemotherapy rather than drug induced toxicity, and she was continued on osimertinib. Conversely, we present a second case of a 57-year-old female with Stage IV lung adenocarcinoma who developed osimertinib-induced pneumonitis and was successfully rechallenged with osimertinib and glucocorticoids. These cases, described herein, illustrate examples of the range of pulmonary manifestations of osimertinib, as well as the safety of rechallenging patients with osimertinib and glucocorticoids following the development of pneumonitis.
Identifiants
pubmed: 31882494
pii: 34/1/315
doi: 10.21873/invivo.11776
pmc: PMC6984067
doi:
Substances chimiques
Acrylamides
0
Aniline Compounds
0
Antineoplastic Agents
0
osimertinib
3C06JJ0Z2O
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
315-319Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
Radiology. 2002 Sep;224(3):852-60
pubmed: 12202725
J Thorac Oncol. 2016 Dec;11(12):2253-2258
pubmed: 27618759
Invest New Drugs. 2017 Dec;35(6):839-841
pubmed: 28466377
Respiration. 2004 Jul-Aug;71(4):301-26
pubmed: 15316202
Intern Med. 2018 Jan 1;57(1):91-95
pubmed: 29033419
J Thorac Oncol. 2017 May;12(5):e59-e61
pubmed: 28434520
Int J Mol Sci. 2019 Aug 17;20(16):null
pubmed: 31426531
J Thorac Oncol. 2018 Aug;13(8):1106-1112
pubmed: 29775809
Cancer Res. 2003 Aug 15;63(16):5054-9
pubmed: 12941834
Respir Med Case Rep. 2017 Dec 11;23:68-70
pubmed: 29487786
Clin Lung Cancer. 2018 Jan;19(1):e53-e55
pubmed: 28736180
J Clin Oncol. 2017 Oct 20;35(30):3484-3515
pubmed: 28806116
N Engl J Med. 2017 Feb 16;376(7):629-640
pubmed: 27959700